About Us
David M. Kendall, MD, Chief Scientific & Medical Officer
Chief Scientific & Medical Officer
David M. Kendall, MD, is currently Chief Scientific & Medical Officer for the American Diabetes Association, the leading nonprofit health organization dedicated to preventing and curing diabetes and to improving the lives of the nearly 24 million children and adults in the United States currently living with the disease and the 57 million with pre-diabetes.
Kendall joined the Association in September 2009 where he provides leadership and oversight of scientific and medical activities including research, clinical affairs, program recognition and certification, medical information and professional education. In this capacity, he oversees the Association’s support of a broad range of professional education activities and the development of the Association’s clinical practice guidelines, clinical consensus reports and expert opinions. Last year, the Association provided $42.5 million in research funds, funding 492 grants at 172 leading US research institutions.
In addition to his role at the American Diabetes Association, Dr. Kendall holds an academic appointment as Associate Professor of Medicine at the University of Minnesota and serves as an Adjunct Medical Director at the International Diabetes Center (both in Minneapolis, MN).
With more than a decade of service to the International Diabetes Center, Dr. Kendall has served as Medical Director and Chief of Clinical and Professional Services (2008-2009), Chief of Clinical Services (2000-2005) and Medical Director, Affiliate Programs (1997-2001). He has also served as Executive Director of Medical Affairs at Amylin Pharmaceuticals (2005-2008). He has also held the position of Consultant in Endocrinology for the Park Nicollet Clinic in Minneapolis and served as full-time faculty at the University of Minnesota Medical School from 1994-1997.
Active in diabetes research, education and clinical care for nearly 25 years, Dr. Kendall’s research interests have emphasized the clinical management of both type 1 and type 2 diabetes, emerging and novel therapies for diabetes care, the treatment and prevention of complications of diabetes and studies of models of diabetes care delivery.
He has authored more than 150 original manuscripts, chapters and professional reviews. Additionally, Dr. Kendall has served as an investigator in both the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications (DCCT/EDIC) Trial and served as a principle clinical investigator for the NHLBI-sponsored Action to Control Cardiovascular Risk in Diabetes (ACCORD) Trial in type 2 diabetes.
